Published in Oncotarget on September 02, 2016
The role of G protein-coupled receptors in lymphoid malignancies. Cell Signal (2017) 0.75
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
Purification and characterization of a heat-shock element binding protein from yeast. EMBO J (1987) 4.43
G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov (2011) 3.31
Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol (2006) 3.19
Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. EMBO J (1996) 3.18
Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Science (1992) 2.77
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. Immunity (2007) 2.65
Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. Genes Dev (2000) 2.55
LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes. Mol Cell Biol (1991) 2.41
IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia (2010) 2.17
Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol (2011) 2.12
Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer (2013) 2.02
Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med (2009) 1.80
The role of the Ikaros gene in lymphocyte development and homeostasis. Annu Rev Immunol (1997) 1.78
Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. J Biol Chem (2003) 1.77
MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity (2010) 1.70
Formation of an active tissue-specific chromatin domain initiated by epigenetic marking at the embryonic stem cell stage. Mol Cell Biol (2005) 1.62
Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol (2002) 1.60
Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity (2001) 1.58
Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. Blood (2013) 1.51
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica (2012) 1.50
Stage-specific control of early B cell development by the transcription factor Ikaros. Nat Immunol (2014) 1.42
Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica (2012) 1.28
Binding of Ikaros to the lambda5 promoter silences transcription through a mechanism that does not require heterochromatin formation. EMBO J (2001) 1.25
A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M. Proc Natl Acad Sci U S A (1998) 1.18
Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells. Radiat Oncol (2012) 1.12
Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell Death Differ (2008) 1.12
GPCR agonists and antagonists in the clinic. Med Chem (2005) 1.10
G2A as a receptor for oxidized free fatty acids. Prostaglandins Other Lipid Mediat (2008) 1.10
Enhanced G2-M arrest by nuclear factor-{kappa}B-dependent p21waf1/cip1 induction. Mol Cancer Res (2005) 1.07
Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia (2012) 1.07
Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. Genes Dev (2010) 1.04
Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation. Cancer Res (1999) 1.03
G2A plays proinflammatory roles in human keratinocytes under oxidative stress as a receptor for 9-hydroxyoctadecadienoic acid. J Invest Dermatol (2007) 1.01
Transcriptional regulation in early B cell development. Curr Opin Immunol (2007) 0.97
G2A is an oncogenic G protein-coupled receptor. Oncogene (2000) 0.97
Foxp1 maintains hair follicle stem cell quiescence through regulation of Fgf18. Development (2013) 0.96
Ikaros is absolutely required for pre-B cell differentiation by attenuating IL-7 signals. J Exp Med (2013) 0.95
Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene. Cancer Cell (2002) 0.92
JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia (2016) 0.89
Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival and Migration. Hum Genomics Proteomics (2009) 0.83
RUNX1 and FOXP3 interplay regulates expression of breast cancer related genes. Oncotarget (2016) 0.78